Newsroom

In this Genetic Engineering & Biotechnology News article, "Downstream Trends and Challenges," the author discusses the increasing complexity and challenges facing manufacturers today. ScaleReady is mentioned as a joint venture designed to better serve cell therapy developers with scaleable, flexible platforms from established partners.

Pharma's Almanac asked industry experts, including ScaleReady's Global Director Josh Ludwig, their thoughts on the most significant regulatory decisions or guidance on the horizon for 2024. Josh discusses establishing more comprehensive and flexible guidelines for CGTs that will provide the clarity needed to enable creative, high-throughput manufacturing strategies.

Before investing in advanced tech, manufacturers must fully understand AI and automation in the unique context of CGT production. Josh Ludwig, Global Director, ScaleReady writes about the importance of simplifying existing CGT manufacturing processes before integrating AI and automation, ensuring a smooth transition.

Josh Ludwig, Global Director of ScaleReady, joins Pharma's Almanac and biopharma industry experts to discuss the most consequential events and results of 2023. Josh reviews how investment setbacks have instigated a pivotal paradigm shift in cell therapy manufacturing this year.

To meet rising patient demand, the cell and gene therapy industry must rapidly scale up production through advancements in automation, talent acquisition, and supply chain management. Genetic Engineering & Biotechnology News discusses advancements in cell therapy industry growth, including the ScaleReady joint venture.

Technology is transforming healthcare, with a major focus on the development of precision medicine. Josh Ludwig, Global Director of ScaleReady, discusses the implications of automation and AI in cell therapy.

The Medicine Maker gathered four experts, including ScaleReady's Josh Ludwig, to discuss what’s changed, what’s changing, and what the future looks like for Industry 4.0 in pharma manufacturing, knowing the industry traditionally lags somewhat in this uptake.

Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?

While innovation drove the early stages of cell therapy development, the industry is now transitioning to address the challenges of delivering these therapies to patients on a large scale. Josh Ludwig of ScaleReady emphasizes the importance of standardized workflows that are scalable and easily automated to improve efficiency.

Automation is necessary for the future of CGT manufacturing to reduce contamination risk. However, as Jenny Stjernberg of ScaleReady highlights in this BioProcess International article, premature automation without simplifying processes can lead to longer timelines, increased risk, and financial strain.

Industry experts, including Jenny Stjernberg, Ph.D., Commercial Director, EMEA, discuss which conventional industry wisdom they believe is misguided, outdated, or just plain wrong with Pharma's Almanac. Jenny discusses how many developers have too-literally retained the conventional wisdom that for cell-based therapies "process is product."

Cell therapies show remarkable potential in treating challenging lymphomas, as demonstrated by real-world data. But companies may run out of funds before reaching milestones due to factors like inefficient manufacturing, facility costs, and difficulties scaling processes. Alaina Schlinker, Ph.D., Senior Manager, Field Applications Support, ScaleReady, discusses how ScaleReady's platforms aim to help developers reach clinical milestones quickly and cost-effectively.